TCTAP A-150 The Efficacy of 2.25mm Everolimus-Eluting Stents for Very Small Vessel Lesions in Real-World Patients  by Shimada, Takenobu et al.
S72 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 5 , N O . 1 7 , S U P P L S , 2 0 1 5TCTAP A-150
The Efﬁcacy of 2.25mm Everolimus-Eluting Stents for Very Small Vessel
Lesions in Real-World Patients
Takenobu Shimada,1 Kazushige Kadota,1 Yu Izawa,1 Takeshi Tada,1
Kazuaki Mitsudo1
1Kurashiki Central Hospital, Japan
BACKGROUND Very small vessel coronary artery disease represents a
challenging entity for treatment with percutaneous coronary inter-
vention. Recently, 2.25 mm platinum chromium everolimus-eluting
stent (PtCr-EES) is available. We evaluated the efﬁcacy of 2.25 mm
PtCr-EES in real-world patients.
METHODS Between September 2012 and February 2014, we treated
247 de novo very small vessel lesions using 2.25 mm PtCr-EES.
Angiographic follow-up was routinely performed at 8 months after
procedure. The follow up rate was 76.5%.
RESULTS The reference diameter was 2.33þ/-0.30 mm, the lesion
length was 23.8þ/-13.7 mm, and the acute gain was 1.55þ/-0.6 mm.
The restenosis rate was just 2.8%, the target lesion revascularization
rate was just 1.0%, and the late lumen loss was 0.22þ/-0.4 mm.
CONCLUSION Based on the 8-month angiographic data, restenosis
and target lesion revascularization rate were low. 2.25 mm PtCr-EES is
considered effective in treating very small vessel lesions.
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BACKGROUND Clinical outcomes in patients treated with drug
eluting stent (DES) implantation between Right coronary artery ostial
(RCAos) lesion and left main coronary ostial (LMos) lesion still un-
clear. The purpose of this study is to compare clinical outcomes of DES
implantation for RCAos lesion and LMos lesion for 5 years.
METHODS A total of 74 consecutive patients with de novo RCAos
lesion or LMos lesion who underwent percutaneous coronary inter-
vention (PCI) with DES from July 2005 to August 2009 were enrolled.
The patients were divided into two groups according to the type of
ostial lesion. (RCAos group; n¼40, LMos group; n¼34). Study end-
points were a composite of major adverse cardiacevents (MACE),
including all-cause death, myocardial infarction (MI), target lesion
revascularization (TLR), target vessel revascularization (TVR) for
5years.
RESULTS There was no signiﬁcant difference between two groups in
baseline characteristics. Cumulative MACE for 5 years in patients withaorto-ostial lesion was higher in RCAos group than LMos group (37.5%
vs. 14.7%, p¼0.028). In RCAos group, the incidences of all-cause death
(15.0% vs. 5.9%, p¼0.518), MI (12.5% vs. 5.9%, p¼0.332), TLR (10.0%
vs. 8.8%, p¼0.863), and TVR (15.0% vs. 11.8%, p¼0.685) were higher
than LMos group (17.8% vs. 5.1%, p¼0.074).
CONCLUSION Long-term clinical outcomes in patients treated with
DES implantation for aorto-ostial lesion seem to be acceptable. A pa-
tient with LMos lesion may have better clinical outcome, however
further study will be needed.
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BACKGROUND Percutaneous coronary intervention (PCI) with drug
eluting stent (DES) in small vessel coronary disease (SVD,
diameter <2.8 mm) is the standard of care with low target lesion
revascularization (TLR) rate of 6-9%. Recently, drug coated balloon
(DCB) has been used to treat de-novo SVD with promising result. We
studied the efﬁcacy and safety of drug coated balloon-only angio-
plasty (DCBA) in SVD amongst high-risk patients.
METHODS We retrospectively analyzed the outcome of consecutive
patients who underwent PCI to de-novo SVD with DCB or DES
sized  2.5 mm in 2013 with 1 year follow up data.
RESULTS One hundred and twenty (120) patients were intervened
with DCBA (100% Sequent Please, BBraun), male 83.3%, mean age
62  11.5 years old; 48% had diabetes mellitus, 70% had hyperlipid-
emia, 75.6% had hypertension and 26% had history of smoking. Three
quarter of the patients presented with acute coronary syndrome
(ACS), unstable angina pectoris/NSTEMI (59.2%) and STEMI (25.8%).
In the DCBA arm, the most common target vessel was LCX (39%),
followed by LAD (36%) and RCA (24%). On average, 1.38 DCB was used
per patient. Mean diameter or DCB was 2.26  0.25 mm and mean
length was 16.3  4.1 mm.
In the same period, 24 patients had DES implantation using stents
diameter  2.5mm. The demographics of the DES patients were not
signiﬁcantly different from the DCBA group. In total 26 devices were
used. Mean diameter of the DES was 2.44  0.1 mm with mean length
of 22.6  8.4 mm.
Despite the predominantly ACS presentation, patients treated with
DCBA had shorter duration of DAPT than the DES group (8.2 months
vs. 12 months, p<0.0001).
At 1 year, 10 MACEs were observed at DEBA arm (8.33%), consisting
of 4 MIs (3%) and 5 TLRs (4.16%). In patients treated with DES, there
was 1 TLR (4.1%) at 1 year, without any other MACE. No death or major
bleeding was found in either group during 1-year period.
CONCLUSION DCBA has similar TLR at 1 year compared to second
generation DES implantation (4.16% vs. 4.16%, respectively, p ¼ 0.74)
in treating SVD in a high-risk group of patients. The DAPT duration
was also shorter using DCBA.
